Advances in treatment strategies for low-grade serous ovarian cancer

Area of Science:

• Gynecologic Oncology
• Molecular Oncology
• Translational Cancer Research

Background:

• Low-grade serous ovarian carcinoma (LGSOC) is a rare subtype of epithelial ovarian cancer (EOC) with distinct molecular features.
• LGSOC exhibits limited sensitivity to conventional chemotherapy, necessitating alternative treatment approaches.
• Genomic profiling has identified key signaling pathway alterations in LGSOC, including MAPK and PI3K.

Purpose of the Study:

• To review the current treatment landscape for LGSOC.
• To explore emerging therapeutic strategies, including targeted agents and endocrine therapies.
• To discuss the integration of molecular biomarkers in LGSOC treatment decision-making.

Main Methods:

• Literature review of recent advances in LGSOC research.
• Analysis of genomic profiling data and clinical trial outcomes.
• Synthesis of evidence on targeted therapies and biomarker-driven approaches.

Main Results:

• Recurrent molecular alterations in MAPK, PI3K, and cell cycle pathways are identified in LGSOC.
• Targeted agents and endocrine strategies show promise in early clinical investigations.
• The rarity of LGSOC presents challenges for developing evidence-based treatment standards.

Conclusions:

• Precision medicine approaches are crucial for advancing LGSOC treatment.
• Biomarker-driven clinical trials are essential for optimizing therapeutic strategies.
• Tailoring treatment based on LGSOC's unique biology is key to improving patient outcomes.